REAL SCIENCE. REAL POSSIBILITIES.An early-stage brain research peptide attracting interest around mood, neurogenesis and cognitive health. Evidence is currently preclinical.
PE-22-28 is unusually specific for an experimental peptide: it was designed from spadin, tested against TREK-1 and compared with its parent sequence. The remaining translation gap is still very large.
These cards show what PE-22-28 is best known for and where the interest comes from. When you want the detail, open Research for the studies or Evidence for a quick view of how strong the support is.
The main reasons this compound attracts attention. The Research and Evidence sections give you the deeper scientific picture.
PE-22-28 was designed to inhibit the two-pore potassium channel TREK-1, a target linked experimentally with mood pathways.
The 2017 study reported an in-vitro IC50 of 0.12 nM and selectivity for TREK-1, but target potency does not predict a safe or effective human dose.
Mouse behavioural tests produced the principal benefit signal associated with PE-22-28.
Reduced immobility in forced-swim testing is an experimental screening outcome, not evidence that depression improves in people.
Short treatment was associated with markers of hippocampal neurogenesis in mice.
The finding supports biological follow-up, but cell-generation markers cannot establish improved mood, cognition or resilience in humans.
The shortened analogue was created to improve stability and activity compared with parent spadin.
Mouse data suggested activity lasting about 23 hours versus roughly seven hours for spadin; human exposure and half-life are unknown.
PE-22-28 improves the potency and experimental persistence of parent spadin in preclinical work. The evidence story is coherent—but it currently ends with cells and mice.
Shortened sortilin-derived spadin analogue
→Sub-nanomolar inhibition in experimental systems
→Behaviour and hippocampal neurogenesis
→No clinical dose, efficacy or safety programme
The attraction is not vague: PE-22-28 was engineered from spadin for stronger TREK-1 inhibition and longer experimental action. The important missing layer is any administered-human evidence.
The original paper reports potent and selective TREK-1 inhibition in its experimental systems.
Antidepressant-like results come from mouse screening tests, not diagnosed human depression.
Hippocampal cell-generation markers provide a follow-up mechanism rather than a clinical outcome.
Human pharmacokinetics, route, dose, efficacy and psychiatric safety remain uncharacterised.
Transfected cells, neuronal preparations and mouse behavioural models
Cell systems, brain slices and mouse models
No registered interventional human programme identified
No administered-human PE-22-28 study was identified.
Antidepressant or cognitive efficacy has not been tested in a controlled human trial.
Human pharmacokinetics, psychiatric adverse effects, interactions and long-term safety are unknown.
Direct cell and mouse work supports TREK-1 blockade, behavioural and neurogenesis hypotheses.
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
No administered-human trial identified
Direct TREK-1, behaviour and neurogenesis work
Human exposure, psychiatric outcomes and long-term safety
A measured biological response can be valuable evidence without establishing a self-administered protocol or a durable treatment benefit.
Mood, motivation and neuroplasticity goals—mapped against one focused analogue study, the parent-spadin literature and a complete human-evidence gap.
Community goals · TREK-1 biology · human boundaryPE-22-28 is discussed around mood, motivation, cognitive flexibility and rapid-onset effects. The strongest available paper supports TREK-1 biology in mice, while every practical human outcome remains anecdotal.
Experiences can reveal recurring goals, perceived changes and practical questions that formal studies may not yet address. They can suggest what deserves investigation, but cannot isolate the effect of one compound from rehabilitation, time or other changes.
Human and preclinical research helps test whether an idea is biologically plausible, whether it appears in people and how confidently the result can be separated from chance, bias or other parts of recovery.
People are drawn to a mechanism that differs from familiar monoamine-focused antidepressants.
No controlled human PE-22-28 mood study was identified.
Mouse screening tests showed antidepressant-like behaviour after PE-22-28.
A coherent animal signal, not evidence of an antidepressant effect in people.
Short-latency reports are often linked to the rapid preclinical spadin story.
No human onset, exposure or dose-response study exists.
The parent and analogue programmes reported rapid behavioural signals in mice.
Timing from animal tests cannot validate a same-day human effect.
Users extend the hippocampal neurogenesis result toward learning and flexible thinking.
No cognitive or neuroimaging endpoint has been tested in people.
Hippocampal neurogenesis markers increased after short treatment in mice.
An interesting biological signal whose practical cognitive meaning is unknown.
Low-microgram nasal routines are repeated because they sound conservative and convenient.
No study validates nasal absorption, spray delivery, cycling or maintenance.
The main paper used experimental animal administration and cannot provide a retail nasal conversion.
A recognizable community pattern with no clinical calibration.
Community reports can surface patterns worth exploring. Controlled human research is what tests whether those patterns are reliable, clinically meaningful and attributable toPE-22-28, while the available studies show how far that question has already been answered.
Compare published study protocols with the patterns people discuss in the community. The two are intentionally kept separate so an anecdotal routine is never mistaken for clinical guidance.
This visual reflects a recurring community pattern. It is not derived from the cell and mouse doses in the published PE-22-28 paper.
Anecdotal intranasal starting amount
Optional community-described step
Upper end of recurring descriptions
No validated cycle or break interval
Delivered micrograms depend on concentration and pump volume. The original PE-22-28 study cannot provide a human nasal conversion.
The source shows what has actually been studied. It does not validate the community example above or turn it into guidance.
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
No human PE-22-28 dose, pharmacokinetic profile, route comparison or treatment duration has been established.
Community protocol summaries often describe 100 mcg intranasally once daily as a cautious starting amount.
Brief four-to-eight-week courses are discussed more often than indefinite use.
Some descriptions insert a two-to-four-week break, but no evidence-based washout or repeat-cycle interval exists.
See the thinking behind community-named stacks, the different role each component is proposed to play, and how much of that idea has actually been tested as a combination.
PE-22-28 + Assessment, psychotherapy and/or prescribed treatment
PE-22-28 + Selank
PE-22-28 + Semax
PE-22-28 has a focused mouse-model story but no human psychiatric efficacy or safety programme.
Clinical assessment and treatment address diagnosed symptoms; Selank or Semax add untested neuroactive uncertainty rather than proven synergy.
People exploring mood effects may be trying to address symptoms that deserve a proper diagnosis and an evidence-based plan.
No study shows PE-22-28 improves standard care; it must not delay urgent help or replace established treatment.Community discussion pairs a TREK-1 mood hypothesis with a calmer-focus peptide narrative.
No human combination study establishes efficacy, interaction safety or dosing.The pairing is framed as mood-pathway plus neuroplasticity support.
Separate preclinical mechanisms do not establish cognitive or mood synergy, and overlapping CNS effects add uncertainty.Suicidal thinking, severe agitation or mania-like change needs prompt professional help.
TREK-1 and neuroplasticity narratives are not combination evidence.
Mood, sleep and cognition are hard to interpret when several CNS-active products start together.
PE-22-28 has direct TREK-1 potency, selectivity and comparative preclinical data rather than only a broad nootropic narrative.
No participant-level mood outcome, pharmacokinetic study or clinical safety programme has been reported.
Activation, sleep disruption, mania-like effects, suicidality, medication interactions, tolerance and repeated-course safety are uncharacterised.
The summary above reflects the human or preclinical evidence currently represented on this profile.
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Depression and major mood change require appropriate care; abrupt psychiatric-medication changes can be harmful.
Suicidal intent, severe agitation, impulsive risk-taking or mania-like symptoms need urgent professional or emergency support.
No validated human nasal exposure exists, while pump delivery, purity and contamination create separate risks.
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
PE-22-28 is presented as a research compound. The MHRA products database should be checked for any future change in authorised status.
MHRA products database ↗Regulatory evaluation of a substance for compounding is separate from approval of a drug for safety and efficacy.
FDA Drugs@FDA database ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.
